VYGR · Voyager Therapeutics, Inc. · Webcasts, Transcripts & Audio
$2.46
+0.01 (+0.41%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$165.14M
Shares
61.62M
Volume · Oct 5
1.39M
Avg daily vol (3M)
571.79K
Voyager Therapeutics, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Voyager Therapeutics, Inc. (VYGR), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲1527.2%
$32.67M
−$12.57M
'19 Q4
20-03-03
▼80%
$6.54M
−$15.93M
'20 Q4
21-02-25
▲329.5%
$28.07M
$5.71M
'21 Q4
22-03-08
▼47.5%
$712,000
−$19.09M
'22 Q2
22-08-04
▲2672.3%
$41.09M
$17.62M
'22 Q3
22-11-08
▼105.5%
$
−$23.63M
'22 Q4
23-03-07
▲22769.3%
$150.48M
$124.04M
'23 Q1
23-05-09
▲581.6%
$4.85M
−$22.21M
'23 Q2
23-08-03
▼88.8%
$4.61M
−$25.90M
'23 Q3
23-11-06
·
$90.06M
$56.40M
'23 Q4
24-02-28
▼87%
$19.52M
−$11.33M
'24 Q1
24-05-13
▲509.5%
$29.58M
−$10.14M
'24 Q2
24-08-06
▲433.8%
$24.63M
−$9.04M
'24 Q3
24-11-12
▼93%
$6.28M
−$34.49M
'24 Q4
25-03-11
▼66.8%
$6.47M
−$31.02M
'25 Q1
25-05-06
LATEST
▼45.7%
$13.37M
−$27.89M
'25 Q3
25-11-10
Conference
Investor event
2026-09-08
Voyager Therapeutics, Inc. (VYGR) September 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q3
2025-11-10
Voyager Therapeutics, Inc. (VYGR) Q3 2025 Earnings Call
Revenue
$13.37M
▼ 45.7% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Voyager Therapeutics, Inc. (VYGR) Q1 2025 Earnings Call
Revenue
$6.47M
▼ 66.8% YoY Diluted EPS
$-0.53
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-11
Voyager Therapeutics, Inc. (VYGR) Q4 2024 Earnings Call Transcript
Positive tone
Tau programs (antibody and silencing)
External tau data readouts
Gene therapy platform and Zolgensma comparison
Revenue
$6.28M*
▼ 93% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Voyager Therapeutics, Inc. (VYGR) Q3 2024 Earnings Call Transcript
Positive tone
Anti-tau antibody VY7523 for Alzheimer's disease
Clinical trial plans and timing
Tau silencing gene therapy program
Revenue
$24.63M
▲ 433.8% YoY Diluted EPS
$-0.16
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Voyager Therapeutics, Inc. (VYGR) Q2 2024 Earnings Call Transcript
Confident tone
Tau silencing gene therapy program
Anti-tau antibody VY7523 program
Neurocrine and other partnerships
Revenue
$29.58M
▲ 509.5% YoY Diluted EPS
$-0.18
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Voyager Therapeutics, Inc. (VYGR) Q1 2024 Earnings Call Transcript
Confident tone
VY-TAU01 anti-tau antibody for Alzheimer's
TRACER capsid platform / BBB delivery
Gene therapy pipeline progress (SOD1-ALS, GBA1, FA)
Revenue
$19.52M
▼ 87% YoY Diluted EPS
$-0.20
▼ 106.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-02-28
Voyager Therapeutics, Inc. (VYGR) Q4 2023 Earnings Call Transcript
Confident tone
Anti-tau antibody (VY-TAU01) for Alzheimer's
Neurocrine partnership (Friedreich's ataxia)
SOD1 ALS gene therapy
Revenue
$90.06M*
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Voyager Therapeutics, Inc. (VYGR) Q3 2023 Earnings Call Transcript
Revenue
$4.61M
▼ 88.8% YoY Diluted EPS
$-0.59
▼ 231.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-03
Voyager Therapeutics, Inc. (VYGR) Q2 2023 Earnings Call Transcript
Revenue
$4.85M
▲ 581.6% YoY Diluted EPS
$-0.51
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-09
Voyager Therapeutics, Inc. (VYGR) Q1 2023 Earnings Call Transcript
Revenue
$150.48M
▲ 22769.3% YoY Diluted EPS
$2.94
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Voyager Therapeutics, Inc. (VYGR) Q4 2022 Earnings Call Transcript
Revenue
$*
▼ 105.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-08
Voyager Therapeutics, Inc. (VYGR) Q3 2022 Earnings Call Transcript
Revenue
$41.09M
▲ 2672.3% YoY Diluted EPS
$0.45
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-04
Voyager Therapeutics, Inc. (VYGR) Q2 2022 Earnings Call Transcript
Revenue
$712,000
▼ 47.5% YoY Diluted EPS
$-0.50
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-08
Voyager Therapeutics, Inc. (VYGR) Q4 2021 Earnings Call Transcript
Revenue
$28.07M*
▲ 329.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q4
2021-02-25
Voyager Therapeutics, Inc. (VYGR) Q4 2020 Earnings Call Transcript
Revenue
$6.54M*
▼ 80% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY19 · Q4
2020-03-03
Voyager Therapeutics, Inc. (VYGR) Q4 2019 Earnings Call
Revenue
$32.67M
▲ 1527.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–17 of 17 webcasts